CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to KURA

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

3

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Advanced Malignant Neoplasm

View Full Landscape
Drug Information

Target Indication

Advanced Malignant Neoplasm

Clinical Trial

NCT04067336

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Tuzodi

Treatment of prolonged, acute, convulsive seizures in adults, adolescents, children and toddlers (from 2 years of age).

View on EMA
EMAPending

Omforro

Conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia and premedication before induction of anaesthesia.

View on EMA
EMA9/4/2011

Buccolam

Treatment of prolonged, acute, convulsive seizures in infants from 3 months to adults.BUCCOLAM must only be used by parents/carers where the patient has been diagnosed to have epilepsy.For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. See section 4.2.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.